Protagonist Therapeutics Inc Stock
Protagonist Therapeutics Inc took a tumble today and lost -€5.000 (-4.130%).
The stock is an absolute favorite of our community with 27 Buy predictions and no Sell predictions.
On the other hand, the target price of 112 € is below the current price of 119.0 € for Protagonist Therapeutics Inc, so the potential is actually -5.88%.
So far the community has only identified positive things for Protagonist Therapeutics Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Protagonist Therapeutics Inc in the next few years
Pros
?
B****
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Comments
Protagonist Therapeutics (PTGX) had its "outperform" rating reaffirmed by Citigroup Inc..
Show more
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (PTGX) had its "buy" rating reaffirmed by TD Cowen.
Show more
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (PTGX) was upgraded by Wolfe Research to "strong-buy".
Show more
Ratings data for PTGX provided by MarketBeat
News
Takeda Pharmaceutical Q1 Earnings Call Highlights
Takeda Pharmaceutical (NYSE:TAK) said its first-quarter fiscal 2026 results were in line with its full-year outlook as growth from
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit
Hedge fund BVF reported a full exit from Protagonist Therapeutics (NASDAQ:PTGX) in its February 17, 2026, SEC filing, selling 2,560,916 shares worth an estimated $170.12 million.
According to its
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance
On Feb. 6, 2026, William D. Waddill, a director at Protagonist Therapeutics (NASDAQ:PTGX), exercised his stock options and immediately sold 20,000 shares, generating a transaction value of